Conventional fluorescence imaging is powerful but faces a fundamental obstacle: biological tissues naturally emit light when illuminated. This autofluorescence can obscure weak signals from fluorescent probes, particularly when researchers attempt to identify very small lesions or image tissue several millimeters beneath the surface. Photoafterglow probes partly address this problem by storing optical energy and releasing it after the excitation light is switched off. Because the tissue is no longer being illuminated during image acquisition, the background can be substantially reduced. However, light used to charge these materials is strongly scattered and absorbed by tissue, limiting how deeply the probes can be activated.

Sonoafterglow systems replace optical excitation with ultrasound, but they also face limitations in reaching and energizing targets throughout the body. Radioafterglow nanoprobes take a different route by using X-rays as the external energy source. X-rays penetrate tissue much more effectively than visible or near-infrared light, allowing the imaging system to charge nanoparticles located deep inside the body. Once the irradiation ends, the particles continue to emit near-infrared light. This delayed emission eliminates the need for real-time excitation during image collection and can therefore suppress much of the tissue background that complicates conventional fluorescence imaging.

The reported radioafterglow nanoprobes are based on a cascade energy-conversion mechanism. Their formulation brings together three functional components: radioabsorbers, radiosensitizers and radioafterglow substrates. Radioabsorbers capture energy from X-rays, while radiosensitizers help convert that energy into a form that can excite the afterglow substrate. The substrate then releases the stored energy as near-infrared light. According to the researchers, the emission peaks at approximately 788 nanometers, a wavelength range that can travel through tissue more efficiently than visible light. The signal has an approximate half-life of 4.8 minutes, providing a practical window for imaging after the X-ray source has been turned off.

The particles are assembled inside amphiphilic polymers using a film rehydration method, a preparation strategy commonly used to package hydrophobic compounds into nanoscale carriers. In this process, the selected molecular components are first incorporated into a thin polymer film. Rehydration then causes the amphiphilic material to organize into nanosized structures that encapsulate the radioafterglow ingredients. The researchers describe the procedure as rapid, taking less than 10 minutes, while also offering control over the concentration of the compounds loaded into the nanoparticles. Because the method does not depend on elaborate layer-by-layer fabrication, it may be easier to scale than some more complex nanomaterial production techniques.

The latest design adds a molecular gate based on hydrogen peroxide. Tumors often contain higher levels of hydrogen peroxide because of altered metabolism, inflammation and oxidative stress. The molecule is not unique to cancer, and its concentration can vary among tissues and disease states, but it is an important marker of the biochemical conditions surrounding many tumors. In the new probes, hydrogen peroxide is used to activate or unmask the afterglow response. This means that the presence of the nanoparticles alone does not necessarily produce a strong signal; instead, the signal is designed to increase where the relevant chemical environment is present. Such activatable probes could help distinguish diseased tissue from surrounding healthy tissue more precisely than particles that emit continuously.

The performance reported for the system is particularly notable at the scale of small lesions. The researchers achieved a signal-to-background ratio of 169, indicating that the detected tumor-associated signal was far stronger than the surrounding background under the described experimental conditions. The probes also supported the imaging and surgical resection of tumors measuring approximately 1 cubic millimeter. That size is significant because early-stage lesions and microscopic residual disease can be difficult to locate during surgery. A probe that highlights small areas of tumor-associated chemistry could eventually complement anatomical imaging and help surgeons identify tissue that is not readily visible by eye.

The energy requirements may offer another advantage. The researchers report that the tumor-specific radioafterglow nanoprobes achieved their results using an X-ray dose 20 times lower than that required for inorganic materials used in comparable radioafterglow approaches. Lower radiation exposure is important for biomedical translation, although the acceptable dose depends on the imaging task, the distribution of the nanoparticles, the equipment and the regulatory setting. The claimed excitation depth reaches up to 15 centimeters, approximately three times deeper than reported for photoafterglow systems. This depth could make the technology relevant to targets located beneath the skin or within larger organs, where optical charging would be severely limited.

The protocol is intended to make the technology reproducible for researchers working across chemistry, biology and materials science. Nanoprobe construction and characterization typically require one to two weeks, followed by another one to two weeks of cell-based assays. Animal experiments are expected to take three to four weeks. These stages include evaluating particle formation and optical performance, testing hydrogen peroxide responsiveness in biological models, assessing cellular compatibility and determining whether the probes accumulate sufficiently in tumors. The workflow reflects the multidisciplinary nature of the platform: successful imaging depends not only on the chemistry of the afterglow materials, but also on nanoparticle delivery, tumor biology, X-ray exposure and image analysis.

Despite its striking results, the technology remains a research-stage platform rather than a clinically approved imaging method. Future studies will need to establish how the nanoparticles behave in humans, how long they remain in the body, how they are cleared, whether they trigger immune reactions and how reliably hydrogen peroxide levels distinguish tumors from inflamed or otherwise abnormal tissue. Researchers will also need to compare the approach with existing surgical imaging technologies and determine whether its deep-tissue sensitivity translates across different cancer types. Even with those questions unresolved, radioafterglow nanoprobes represent a significant conceptual advance: they use penetrating X-rays to charge a delayed near-infrared signal, then use tumor chemistry to decide where that signal appears. If the strategy survives further testing, it could provide surgeons and oncologists with a new way to see hidden cancer while keeping the imaging background exceptionally low.

Subject of Research: Tumor-specific radioafterglow nanoprobes for deep-tissue imaging of hydrogen peroxide and image-guided cancer surgery

Article Title: Synthesis of radioafterglow nanoprobes for deep-tissue imaging of hydrogen peroxide

Article References: Bai, S., Lin, Y., Xu, C. et al. Synthesis of radioafterglow nanoprobes for deep-tissue imaging of hydrogen peroxide. Nature Protocols (2026). https://doi.org/10.1038/s41596-026-01421-2

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41596-026-01421-2

Keywords: radioafterglow nanoprobes, deep-tissue imaging, hydrogen peroxide, cancer imaging, molecular imaging, X-ray excitation, near-infrared afterglow, image-guided surgery, tumor microenvironment, nanomedicine

The foundation of this breakthrough rests on engineered nanobodies: minuscule, highly specific protein fragments capable of binding targeted molecules within cells. Unlike conventional fluorescent probes that often emit unwanted background signals even when unbound, these synthetic nanobodies remain non-fluorescent until they bind their designated target. This binding-activated fluorescence significantly suppresses noise, enhancing the contrast and fidelity of live imaging results. By reducing nonspecific background fluorescence by an estimated hundredfold, VIS-Fbs enable unparalleled visualization of subcellular events in real time.

Moreover, the team designed a suite of VIS-Fbs that collectively span nearly the entire visible light spectrum, from vivid blues to far reds. This multicolor capacity permits concurrent tracking of numerous molecular targets within a single cell or tissue context, offering researchers a multiplexed window into the intricate choreography of protein interactions and signaling networks. Additionally, certain VIS-Fb variants possess photoswitchable properties, allowing scientists to toggle fluorescence on or off using light, thereby enabling spatially and temporally precise analysis of dynamic cellular processes.

This modular platform was meticulously validated across diverse mammalian cell types and in living animal models, including mice and zebrafish. In murine neurons and astrocytes, the VIS-Fbs uniquely facilitated selective labeling and ratiometric imaging of calcium signaling pathways during behavioral experiments, illuminating the complex neurochemical dialogues underpinning cognition and reflex. Similarly, in zebrafish larvae, the probes captured real-time shifts in developmental signaling and pharmacological responses, demonstrating the method’s versatility across species and experimental conditions.

Dr. Axel Nimmerjahn, co-corresponding author and Françoise Gilot-Salk Chair at the Salk Institute, highlighted how VIS-Fbs overcome longstanding challenges in live-cell imaging. “By harnessing the specificity of antigen binding to stabilize fluorescent signals only upon target engagement, we achieve unprecedented clarity in protein localization without cumbersome background,” Nimmerjahn explained. The result is a robust and adaptable imaging toolkit poised to transform biological research, providing insights into molecular mechanisms driving health and disease progression.

Co-corresponding author Vladislav Verkhusha of Albert Einstein College of Medicine emphasized the platform’s potential to unlock previously inaccessible biological phenomena. The ability to visualize multiple protein targets simultaneously with spatial and temporal control opens new investigative pathways into cellular signaling cascades, developmental biology, and neurobiology. This advanced methodology supports precise dissection of molecular events in intact, living tissue environments, bridging the gap between traditional in vitro assays and complex physiology.

Technically, VIS-Fbs represent a clever integration of molecular engineering and optical innovation. The nanobody scaffold was optimized for strong yet reversible antigen binding, minimizing unbound probe fluorescence. Meanwhile, the fluorescent proteins fused to these nanobodies were selected and engineered to emit bright, stable signals only upon target binding, thereby minimizing photobleaching and off-target activation. This chemical and biological synergy yields a highly sensitive yet robust imaging probe adaptable to diverse experimental demands.

Furthermore, the researchers established a modular design framework allowing quick customization of VIS-Fb probes for new targets and functional outputs. By exchanging nanobody modules or fluorescent proteins, scientists can tailor probes for different molecular markers, cellular compartments, or signaling events. This versatility promises to accelerate imaging-driven discoveries and expand the usability of VIS-Fbs across myriad biomedical disciplines.

The implications of this development are vast. Accurate live-cell imaging is vital for understanding disease mechanisms at the molecular level, including cancer progression, neurodegenerative disorders, and infectious diseases. Enhanced precision in visualizing protein behavior and interactions can offer early-stage insights essential for therapeutic intervention and drug development. VIS-Fbs thus represent a potent new tool for both fundamental research and translational medicine.

In summary, the visible-spectrum antigen-stabilizable fluorescent nanobody technology represents a transformative advance in live-cell microscopy. By combining multicolor fluorescence with target-dependent signal activation and photoswitchability, researchers now have a powerful platform for high-resolution, low-noise imaging of protein dynamics in diverse living systems. This innovation sets the stage for breakthroughs in our understanding of cellular function, development, and disease etiology.

The findings were published in the journal Nature Methods on April 22, 2026, reflecting the collaborative effort of multiple research groups committed to pushing the boundaries of bioimaging technology. Supported by prominent funding agencies and foundations, this work underscores the importance of interdisciplinary cooperation in addressing complex biological questions.

As this vibrant imaging platform gains adoption, it is expected to accelerate new discoveries across life sciences, enabling scientists to observe the molecular dance of life with unmatched clarity and precision. Such tools are instrumental in peeling back the cellular veil, revealing the exquisite details that dictate health, function, and the genesis of disease.

Subject of Research: Development and application of visible-spectrum antigen-stabilizable fluorescent nanobodies for high-specificity, low-background live-cell imaging.

Article Title: Synthetic multicolor antigen-stabilizable nanobody platform for intersectional labelling and functional imaging

News Publication Date: April 22, 2026

Web References:

• Nature Methods Article
• DOI: 10.1038/s41592-026-03056-3

Image Credits: Salk Institute

Keywords: Life sciences, Biophysics, Bioluminescence, Cell biology, Applied physics, Applied optics, Optical microscopy, Nanotechnology, Imaging, High resolution imaging, Live cell imaging, Molecular imaging